Two New Diabetes Drugs Benefit For The Heart And Kidneys

WATERTOWN, Mass. - Oct. 21, 2020 - PRLog -- Two new medications commonly used to treat type 2 diabetes are similar in their ability to reduce major heart complications, including heart attack, stroke and death from cardiovascular disease, according to research accepted for presentation at ENDO 2020, the Endocrine Society's annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.

One class of drugs, known as SGLT2 inhibitors, has a clear benefit over the other class, known as GLP-1 drugs, in reducing hospitalization for heart failure, the study found.

SGLT2 inhibitors are prescription oral medications used to treat type 2 diabetes. They include canagliflozin (Invokana), dapagliflozin (Farxiga) and empagliflozin (Jardiance). The study compared these drugs with injected diabetes drugs known as GLP-1 receptor agonists. These include albiglutide (Tanzeum), dulaglutide (Trulicity), exenatide (Byetta), liraglutide (Victoza) and semaglutide (Ozempic).

In prior studies, it was found that these two classes of drugs showed heart and kidney benefits besides controlling the blood sugar.

The researchers analyzed data from six previous trials of GLP-1 (including a total of 51,762 subjects) and four trials of SLGT2 inhibitors (including 33,457 subjects). Both drug classes were equally effective in reducing combined major adverse cardiac events such as heart attack, stroke and death from cardiovascular disease, compared to people with diabetes who were not taking the drugs.

The rate of hospitalization for heart failure was 32% less in patients taking SLT2 inhibitors compared to patients not taking the drugs, especially in those with more severe cardiovascular disease risk. In contrast, people taking GLP-1 drugs did not have a reduced rate of hospitalization for heart failure compared with people who had diabetes but were not taking the drugs. Both classes of drugs demonstrated kidney benefit; neither class was superior.

The most common serious side effects for SGLT2 inhibitors included yeast infections in women and diabetic ketoacidosis, a rare life-threatening problem that can affect people with diabetes. The major serious side effect for GLP-1 drugs was stomach upset.

Semaglutide is an analogue of the natural hormone GLP-1. GLP-1, a peptide hormone secreted by intestinal cells, stimulates the secretion of insulin and inhibits the secretion of glucagon by binding to the GLP-1 receptor, thereby promoting glucose metabolism. At the same time, it can also delay gastric emptying and suppress appetite.

Biochempeg supplies polyethylene glycol (PEG) derivatives, monodisperse PEGs, custom PEG derivative synthesis and PEGylation services worldwide, from R&D through GMP commercial quantities, for preclinical, clinical trials, and commercial products for pharma, biotech, medical devices, and diagnostics. And, Biochempeg now provides semaglutide key intermediates ( with the best price and high quality.

Company: Biochempeg Scientific Inc.
Address: 108 Water Street, Room 4D, Watertown, MA 02472, USA

Biochempeg Scientific Inc.
Posted By:*** Email Verified
Tags:Semaglutide Key Intermediates
Location:Watertown - Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse

Like PRLog?
Click to Share